S. Korean Court Nears Final Ruling on $35M Claim Against PMI, BAT, KT&G

Apr.23.2025
S. Korean Court Nears Final Ruling on $35M Claim Against PMI, BAT, KT&G
South Korea’s National Health Insurance Service (NHIS) filed a lawsuit seeking about 50 billion won (approximately USD 35 million) in damages against Korea Tobacco & Ginseng (KT&G), Philip Morris International Korea, and British American Tobacco Korea, arguing that these companies should reimburse the treatment costs for patients with smoking-related cancers . Originally lodged in April 2014, the case has spanned 11 years and has now entered the final oral-argument phase at the appellate level.

Key points:

Background and scale of the case: The National Health Insurance Service (NHIS) of South Korea has filed a lawsuit since 2014 against KT&G, Philip Morris International (PMI) Korea (Philip Morris Korea), British American Tobacco Korea (BAT Korea), and others, seeking compensation of 533 billion Korean won (approximately 38 million US dollars). The reason for the lawsuit is that NHIS has paid for treatment expenses for patients suffering from smoking-related cancers.

 

First instance and second instance results: The first instance court found it difficult to confirm a direct causal relationship between smoking and cancer, supporting the tobacco company's position. In the second instance, the healthcare organization presented testimonies from an 86-year-old patient, asserting that there were no other contributing factors to their cancer besides a long history of smoking, in an attempt to strengthen the causal relationship.

 

Controversy over ingredients and court ruling: The first trial also involved a dispute over the responsibility of tar and nicotine in tobacco. The court believed that nicotine is a core attribute of tobacco products and cannot be used as a basis for establishing liability for infringement.


According to N. News, the South Korean National Health Insurance Service (NHIS) has entered the final stage of a lawsuit seeking approximately 500 billion Korean won (approximately 35 million US dollars) in compensation from multiple tobacco companies. The Chief Judge of the Civil 6-1 Division of the Seoul High Court will hold a final round of debates on May 22, after which the date for the ruling on the case will be determined.

 

The case has been ongoing for 11 years since it was filed in April 2014. NHIS is seeking a claim of approximately 533 billion Korean won from KT&G, Philip Morris International (PMI) Korea, and British American Tobacco Korea to reimburse the medical expenses paid by the organization from 2003 to 2013 for 3,465 patients with lung cancer (small cell carcinoma, squamous cell carcinoma) and throat cancer (squamous cell carcinoma).

 

The central dispute of the lawsuit focuses on the causal relationship between smoking and the development of cancer, as well as whether tobacco companies should be held legally responsible for this.

 

In November 2020, the Seoul Central District Court ruled in the first instance that it is difficult to establish a direct causal relationship between smoking and cancer, therefore rejecting all claims of NHIS. The court believed that cancer may be caused by genetics, lifestyle, or other environmental factors. In the first instance, NHIS also argued that tobacco companies did not effectively reduce tar and nicotine levels, but instead added flavor enhancers to enhance the taste. However, the court considered that consumers actively seek the pharmacological sedative effects of nicotine, so this component is inherent to tobacco products and it is difficult to hold tobacco companies accountable for it.

 

NHIS subsequently filed an appeal in December of the same year. In the second trial, NHIS submitted a statement from lung cancer patient A, who is over 80 years old, as additional evidence, attempting to prove that A's lung cancer had no other obvious causes besides smoking. The statement pointed out that A had been smoking for decades since his twenties, although he quit smoking in the late 1990s, he was diagnosed with lung cancer in 2010, and had no relevant family medical history.

 

Currently, South Korean judicial authorities tend to attribute the responsibility for diseases caused by smoking to individuals. In 2014, the South Korean Supreme Court ruled in a similar lawsuit filed by 30 patients against KT&G that smokers must bear the health consequences themselves and did not support their compensation claim.

 

In 1998, the government of all 50 states in the United States jointly filed a lawsuit against tobacco companies including Philip Morris International (PMI) and Reynolds Tobacco, eventually reaching a $246 billion settlement agreement. This result was partially influenced by the "Tobacco Industry Documents," released by internal researchers in 1994, prompting the public to reassess the addictive nature and harm of tobacco products.

 

NHIS believes that this lawsuit is not only legally significant but also helps to raise public awareness on smoking cessation. NHIS is currently promoting a "1 million national support signature campaign" in order to create public opinion support for the upcoming second trial judgment.

 

The tobacco company, on the other hand, stated that they will participate in the second appeal process "honestly".

 

It is reported that the National Health Insurance Service (NHIS) of Korea is a national public institution under the Ministry of Health and Welfare, responsible for the nationwide operation and management of health insurance. Its main duties include providing medical insurance services to the public, collecting insurance premiums, and overseeing settlements with medical institutions.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09
CCPIT Says Trade Friction Index for China-Related Electronics Sector Remains High, With Vape Products Among Areas of Focus
CCPIT Says Trade Friction Index for China-Related Electronics Sector Remains High, With Vape Products Among Areas of Focus
China Council for the Promotion of International Trade (CCPIT) held its July regular press conference on July 31, 2026, releasing the May 2026 Global Economic and Trade Friction Index. CCPIT spokesperson Yang Fan said the global trade friction index stood at 95 in May, remaining at a medium-to-high level. By industry, the electronics sector recorded the highest trade friction index among 13 monitored industries. In China-related trade frictions, the index stood at 93, with electronics products including drones, chips and vape products among areas where friction remained elevated.
Aug.03
Product | JTI Philippines Expands Nordic Spirit Nicotine Pouch Portfolio With Dark Pop and Red Frost
Product | JTI Philippines Expands Nordic Spirit Nicotine Pouch Portfolio With Dark Pop and Red Frost
JTI Philippines has expanded the Nordic Spirit nicotine pouch portfolio in the Philippines with two new variants, Dark Pop and Red Frost. Both products maintain the brand’s tobacco-free nicotine pouch positioning, with Dark Pop featuring a fizzy cola profile with citrus and sweet notes, while Red Frost combines cool mint with sweet red berry flavors. The two variants are now available through Philippine online retail channels.
Aug.18
Product | IVG Launches NEXiO Prefilled Pod System, Expanding Beyond Disposable Vapes
Product | IVG Launches NEXiO Prefilled Pod System, Expanding Beyond Disposable Vapes
UK vape brand IVG has launched the NEXiO reusable prefilled pod system, expanding its product portfolio beyond disposable vape products. The device features a 1,000mAh rechargeable battery, prefilled pods with a refill reservoir structure and a claimed capacity of up to 10,000 puffs. Officially launched in the UK on July 9, 2026, NEXiO debuted with 17 flavor options, reflecting IVG’s move into reusable pod formats.
Aug.19
Australia’s Victoria Steps Up Illegal Tobacco Enforcement With Store Closures and Penalties of Up to A$2.5 Million
Australia’s Victoria Steps Up Illegal Tobacco Enforcement With Store Closures and Penalties of Up to A$2.5 Million
Australia’s state of Victoria has activated new powers allowing Tobacco Licensing Victoria and police to shut premises suspected of selling, supplying or possessing illicit tobacco for up to 90 days. Longer closures can be ordered by a magistrates’ court. Businesses subject to closure orders must generally cease all trading and will be placed on a public list. Breaching a closure order can carry penalties of up to A$2.5 million and 20 years in prison.
Sep.10
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
The U.S. Court of Appeals for the Ninth Circuit upheld the FDA’s denial of MH Global LLC’s applications to market flavored electronic nicotine delivery systems (ENDS). The court ruled that FDA’s comparative-efficacy framework, which requires applicants to show that flavored products provide greater cessation or switching benefits than tobacco-flavored alternatives, is consistent with the Tobacco Control Act’s “appropriate for the protection of the public health” standard. The court also found that FDA was not required to establish the framework through notice-and-comment rulemaking.
Aug.26